Catastrophic APS in the Context of Other Thrombotic Microangiopathies

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2015 Jan 22

PMID 25604575

Citations 13

Authors

Ignasi Rodriguez-Pinto

Gerard Espinosa

Ricard Cervera

Affiliations

Soon will be listed here.

Abstract

The catastrophic antiphospholipid syndrome (CAPS) is a rare disease that affects 1 % of cases with antiphospholipid syndrome (APS). CAPS can mimic or overlap with different thrombotic diseases; many patients present with a microthrombotic storm or thrombotic microangiopathic hemolytic anemia (TMHA). Thus, the differential diagnosis of CAPS includes thrombotic thrombocytopenic purpura (TTP), typical and atypical hemolytic uremic syndrome (HUS), systemic infections, malignancies, pregnancy-related disorders, malignant hypertension, heparin-induced thrombocytopenia, and drug-induced thrombotic microangiopathies. Antiphospholipid antibody (aPL) positivity has been proposed as the clue in this differential diagnosis; however, aPL can also occur in healthy people and in those with infections or malignancies. Thus, the differential diagnosis of an aPL-positive patient presenting with a microthrombotic storm is broad; the workup should include a special attention to signs of infection and disseminated malignant disease, assessing the funduscopic signs of malignant hypertension, testing ADAMTS13 activity and anti-heparin-platelet factor 4 (HPF4) antibodies, and searching previous exposure to certain drugs. This article aims to review the main diseases included in the differential diagnosis of CAPS in the context of other thrombotic microangiopathies.

Citing Articles

The Phenomenon of Thrombotic Microangiopathy in Cancer Patients.

Vorobev A, Bitsadze V, Yagubova F, Khizroeva J, Solopova A, Tretyakova M Int J Mol Sci. 2024; 25(16).

PMID: 39201740 PMC: 11354439. DOI: 10.3390/ijms25169055.

Catastrophic antiphospholipid syndrome after pregnancy complicated by hemolysis, elevated liver enzymes and low platelets syndrome.

Saini A, Wilkie G, Dumont T Obstet Med. 2024; 17(2):124-128.

PMID: 38784193 PMC: 11110754. DOI: 10.1177/1753495X221137941.

Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.

Naranjo L, Stojanovich L, Djokovic A, Andreoli L, Tincani A, Maslinska M Front Immunol. 2022; 13:957201.

PMID: 36172349 PMC: 9511106. DOI: 10.3389/fimmu.2022.957201.

COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?.

El Hasbani G, Taher A, Jawad A, Uthman I Clin Med Insights Arthritis Musculoskelet Disord. 2020; 13:1179544120978667.

PMID: 33328777 PMC: 7720319. DOI: 10.1177/1179544120978667.

The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?.

Previtali G, Seghezzi M, Moioli V, Sonzogni A, Cerutti L, Marozzi R Thromb Res. 2020; 194:192-194.

PMID: 32788116 PMC: 7319923. DOI: 10.1016/j.thromres.2020.06.042.

References

Miesbach W, Asherson R, Cervera R, Shoenfeld Y, Puerta J, Bucciarelli S . The catastrophic antiphospholipid (Asherson's) syndrome and malignancies. Autoimmun Rev. 2006; 6(2):94-7. DOI: 10.1016/j.autrev.2006.06.012. View

Cooling L, Gay S, Silver S . Transfusion medicine illustrated: An imPRESsive mimic. Transfusion. 2010; 50(1):11-2. DOI: 10.1111/j.1537-2995.2009.02362.x. View

Gomez-Puerta J, Espinosa G, Cervera R . Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin Lab Med. 2013; 33(2):391-400. DOI: 10.1016/j.cll.2013.01.003. View

Arepally G, Ortel T . Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006; 355(8):809-17. DOI: 10.1056/NEJMcp052967. View

Gasser C, Gautier E, Steck A, SIEBENMANN R, Oechslin R . [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr. 1955; 85(38-39):905-9. View

Matsuda J, Sanaka T, Gohchi K, Matsui K, Uchida S, Matsumoto M . Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease. Lupus. 2002; 11(7):463-4. DOI: 10.1191/0961203302lu230xx. View

McKenzie S, Sachais B . Advances in the pathophysiology and treatment of heparin-induced thrombocytopenia. Curr Opin Hematol. 2014; 21(5):380-7. PMC: 4232774. DOI: 10.1097/MOH.0000000000000066. View

Gracia P . Acute fatty liver and HELLP syndrome: two distinct pregnancy disorders. Int J Gynaecol Obstet. 2001; 73(3):215-20. DOI: 10.1016/s0020-7292(01)00364-2. View

Bianchi V, Robles R, Alberio L, Furlan M, Lammle B . Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002; 100(2):710-3. DOI: 10.1182/blood-2002-02-0344. View

10.

Gomez-Puerta J, Cervera R, Espinosa G, Asherson R, Garcia-Carrasco M, da Costa I . Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis. 2007; 66(6):740-6. PMC: 1954660. DOI: 10.1136/ard.2006.061671. View

11.

Rieger M, Mannucci P, Kremer Hovinga J, Herzog A, Gerstenbauer G, Konetschny C . ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106(4):1262-7. DOI: 10.1182/blood-2004-11-4490. View

12.

Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A . Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood. 2001; 98(6):1828-35. DOI: 10.1182/blood.v98.6.1828. View

13.

Levi M, Schultz M, van der Poll T . Sepsis and thrombosis. Semin Thromb Hemost. 2013; 39(5):559-66. DOI: 10.1055/s-0033-1343894. View

14.

van den Born B, Koopmans R, Groeneveld J, van Montfrans G . Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006; 24(11):2299-304. DOI: 10.1097/01.hjh.0000249710.21146.38. View

15.

Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L . Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). 2007; 86(4):242-251. DOI: 10.1097/MD.0b013e3181441a68. View

16.

Taylor Jr F, Toh C, Hoots W, Wada H, Levi M . Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2002; 86(5):1327-30. View

17.

Starakis I, Mazokopakis E, Siagris D, Liossis S, Karatza C, Antonopoulos A . Catastrophic antiphospholipid syndrome presented with severe hypertension, adult respiratory distress syndrome and unilateral adrenal haemorrhagic infarction. Rheumatol Int. 2007; 27(8):781-3. DOI: 10.1007/s00296-007-0348-z. View

18.

Anderson Jr F, Spencer F . Risk factors for venous thromboembolism. Circulation. 2003; 107(23 Suppl 1):I9-16. DOI: 10.1161/01.CIR.0000078469.07362.E6. View

19.

Bourhim M, Darnige L, Legallais C, Arvieux J, Cevallos R, Pouplard C . Anti-beta2-glycoprotein I antibodies recognizing platelet factor 4-heparin complex in antiphospholipid syndrome in patient substantiated with mouse model. J Mol Recognit. 2003; 16(3):125-30. DOI: 10.1002/jmr.619. View

20.

Montecucco C, Di Lauro M, Bobbio-Pallavicini E, Longhi M, Caporali R, De Gennaro F . Anti-phospholipid antibodies and thrombotic thrombocytopenic purpura. Clin Exp Rheumatol. 1987; 5(4):355-8. View